Fountain Pharmaceuticals (FPHI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Fountain Pharmaceuticals (FPHI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark Fisner who wrote ()	12/28/1997 6:52:00 AM
From: r. peter Dale	Read Replies (1) of 78

In the article covered by Michael Gilman's (Ariad) perspective in the 9 December PNAS (http://www.pnas.org/cgi/content/full/94/25/13402), the authors use a liposome carrier to "...enhance cell permeability". The experiment was to deliver a highly specific (D enantiomer, i.e., resistant to intracellular proteolysis) drug to cells in culture (see p. 13404). The results indicate such finely targeted drug delivery systems hold great potential. For Fountain, these data strongly suggest that their liposome carriers could be put use in treating localized dermatological pathologies. Since Fountain has already shown their Liposome construct does not penetrate beyond a certain layer of skin, the likeihood of uncontaminated local effects - and thus interpretable in vivo data - would appear to be good. At a minimum, such an approach could serve as a valuable model for the targeted delivery of pharmaceuticals. I'll contact Walsh @ Fountain and suggest he call Gilman re possible collaboration. Seems possible that FPHI is not quite comprehending the potential of the their little bubble of fat. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next